Trading Halted on CitiFirst MINI Long 4DKOE Linked to 4DMedical After Stop Loss Event on 2 July 2026

Details Behind the Stop Loss Event on 2 July 2026 for the 4DMedical MINI Long

Citigroup Global Markets Australia Pty Limited explained that a Stop Loss Trigger Event occurs when the underlying parcel price of the security linked to a CitiFirst MINI Long trades at or below the predetermined Stop Loss Trigger Level. For this product, the underlying security is 4DMedical Ltd, with a Stop Loss Level set at $3.9100 per parcel. The announcement confirms this threshold was breached on 2 July 2026, activating the product’s suspension mechanism as specified in the Terms of Issue.

The CitiFirst MINI Long structure is designed to immediately suspend trading when the underlying asset’s price hits or falls below the stop loss level, protecting both issuer and investors from further adverse price movements beyond the defined risk limit. This is a standard feature of leveraged structured products and does not indicate any fault by holders. The event is automatic and governed solely by 4DMedical Ltd’s share price relative to the pre-established level disclosed at issuance.

Key Terms of the Suspended 4DKOE CitiFirst MINI Long

The suspended product, trading under ASX code 4DKOE, is linked to 4DMedical Ltd (ASX:4DX). The Strike Price and Final Instalment are $3.1254, with a Conversion Ratio of 1, meaning each MINI represents one unit of the underlying parcel. The Stop Loss Level per parcel, now breached, was $3.9100.

These figures are critical for holders to understand the Cash Amount or Stop Loss Amount they may receive. The announcement does not specify the exact Stop Loss Amount payable, as it is calculated according to the CitiFirst MINI Terms of Issue at the time of the event. Investors seeking details on their entitlement should contact their adviser or call CitiFirst directly at 1300 30 70 70.

Temporary Trading Resumption Window for 4DKOE Holders

Following suspension, Citigroup has outlined a process for holders to exit their positions. Per the Terms of Issue, Citi will display a bid at the Cash Amount level—referred to as the Stop Loss Amount—from 2pm on the next trading day after the trigger. This bid will remain open until 4pm on the following trading day, termed the Stop Loss Trading Close.

During this limited resumption window, holders can sell their MINI Long back to Citi on the ASX at the Stop Loss Amount, providing an orderly exit option. Missing this window does not forfeit entitlement; instead, the process moves to automatic payment as described in the Terms of Issue.

Automatic Payment If Holders Do Not Sell During Resumption

Holders who do not sell during the Stop Loss Trading Close will receive the Stop Loss Amount per MINI from Citigroup within 10 business days after the trading day following the trigger event. Upon payment, the MINI Long will expire automatically.

This ensures all holders receive payment either through selling during the resumption window or via automatic settlement. The announcement does not disclose the dollar value of the Stop Loss Amount, as it is calculated under the product’s Terms of Issue based on market conditions at the time. Holders uncertain about their entitlement should review their product documentation or contact CitiFirst.

Role of 4DMedical Ltd in the Stop Loss Trigger

4DMedical Ltd’s share price performance directly caused the Stop Loss Trigger Event on the 4DKOE MINI Long. The company update does not comment on reasons for 4DMedical’s share price movement or why the parcel price breached $3.9100. The announcement focuses solely on the structured product event and Citigroup’s issuer obligations.

Investors holding 4DMedical shares directly, rather than through the MINI product, are unaffected by this event. The suspension and termination process applies only to holders of the 4DKOE CitiFirst MINI Long. The breach indicates 4DMedical’s share price traded at or below $3.9100 during the trading session on 2 July 2026. Public information does not clarify the immediate share price impact beyond this.

Citigroup’s Issuer Responsibilities Under the CitiFirst MINI Framework

Citigroup Global Markets Australia Pty Limited (ABN 64 003 114 832, AFSL 240992) issues the full range of CitiFirst structured products listed on the ASX, including MINIs, Structured Finance Investments, Trading Warrants, Turbos, and Instalments. As a participant in the ASX Group and Cboe Australia, Citigroup complies with market integrity rules and disclosure obligations for listed structured products.

This company update fulfills Citigroup’s duty to notify the ASX and holders of a material product event—the Stop Loss Trigger and resulting suspension. The notification was addressed to Andrew Weaver at ASX Warrants, Level 6, 20 Bridge Street, Sydney, following standard procedures. Citigroup’s disclosure confirms ongoing obligations to holders through payment of the Stop Loss Amount, whether via temporary trading or automatic settlement within 10 business days.

Next Steps for Holders of the 4DKOE MINI Long

Holders of the suspended 4DKOE CitiFirst MINI Long can choose to sell during the temporary trading window or await automatic expiry and payment within 10 business days. The bid from Citi will be available from 2pm on the next trading day after 2 July 2026 and close at 4pm the following day.

Those unsure of their preferred action are advised to consult their financial adviser or contact CitiFirst at 1300 30 70 70. Due to the limited duration of the trading window, prompt action is recommended for holders wishing to transact on-market instead of waiting for cash settlement. Reviewing the product’s Terms of Issue is important to understand the Stop Loss Amount calculation and any applicable conditions.

Context on MINI Long Products and Stop Loss Features on the ASX

CitiFirst MINI Long products are leveraged instruments enabling investors to gain exposure to an underlying security with lower capital outlay than direct share ownership. They carry risks, notably the Stop Loss Trigger mechanism, a risk management feature that suspends and terminates the product if the underlying price falls to the pre-set Stop Loss Level. This prevents losses beyond the product’s defined limits.

This differs from traditional shareholding, where investors can hold through price declines without mandatory exit. Investors in such structured products should be aware that Stop Loss events can occur suddenly during periods of share price volatility. The 4DKOE event illustrates how these mechanisms function in practice and highlights the importance of monitoring the underlying security’s market price relative to stop loss thresholds.

No Financial Guidance or Impact Disclosed by Citigroup

The company update does not include forward-looking statements, earnings guidance, revenue data, or commentary on financial impacts of the Stop Loss Event on Citigroup or 4DMedical Ltd. It is a procedural notice concerning the structured product event and issuer obligations.

Details such as the total number of 4DKOE MINI Long units issued, aggregate Stop Loss Amount payable, or trading volumes at suspension were not disclosed. Investors seeking detailed product information should consult the original CitiFirst MINI Terms of Issue lodged with the ASX at product listing. The next key date for holders is the opening of the temporary bid window at 2pm on the trading day following 2 July 2026.